AI Article Synopsis
- Idiopathic focal segmental glomerulosclerosis (FSGS) is a significant cause of kidney failure in adults and often recurs after kidney transplants, with limited treatment options for those who don't respond to standard therapies.
- A case study of a 44-year-old man showed that after multiple failed treatments for recurrent FSGS post-transplant, he experienced an unexpected partial remission after starting ofatumumab, which is a newer treatment.
- The observation suggests that ofatumumab might be a viable alternative for patients who are resistant to existing treatments like plasmapheresis and rituximab.
Article Abstract
Background: Idiopathic focal segmental glomerulosclerosis is an important cause of kidney failure in adults, which is associated with a high risk of disease recurrence after transplantation. Plasmapheresis, rituximab, immunoadsorption, and high-dose cyclosporine are used to treat post-transplant recurrent focal segmental glomerulosclerosis (rFSGS). However, the response rate is variable, and few options remain for unresponsive patients.
Case Report: We present a 44-year-old man with an early post-transplant rFSGS. After peritransplant plasmapheresis, rituximab, and abatacept treatments failed, we employed ofatumumab. After 9 months without apparent benefit, we observed an unexpected partial remission thereafter, without severe side effects. Furthermore, remission has been sustained in 30-month follow-up.
Conclusions: We believe ofatumumab can be considered an alternative for patients with plasmapheresis and rituximab-resistant post-transplant rFSGS.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.transproceed.2022.04.019 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!